Market News

Emerald Advisers Has Trimmed Caretrust Reit (CTRE) Holding By $796,860; Profile of 4 Analysts Covering Idera Pharmaceuticals, Inc. (IDRA)

Among 4 analysts covering Idera Pharma (NASDAQ:IDRA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 7 analyst reports since January 6, 2016 according to SRatingsIntel. The firm earned “Outperform” rating on Wednesday, February 1 by Wedbush. The rating was maintained by H.C. Wainwright on Thursday, November 16 with “Buy”. Piper Jaffray maintained Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) on Thursday, November 9 with “Buy” rating. The firm has “Outperform” rating by Wedbush given on Wednesday, January 6. Piper Jaffray maintained the stock with “Buy” rating in Monday, September 11 report. See Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) latest ratings:

16/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4 Initiates Coverage On
11/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain

Emerald Advisers Inc decreased Caretrust Reit Inc (CTRE) stake by 3.42% reported in 2017Q3 SEC filing. Emerald Advisers Inc sold 41,940 shares as Caretrust Reit Inc (CTRE)’s stock rose 20.21%. The Emerald Advisers Inc holds 1.18 million shares with $22.56M value, down from 1.23M last quarter. Caretrust Reit Inc now has $1.15B valuation. The stock decreased 1.50% or $0.23 during the last trading session, reaching $15.14. About 911,542 shares traded or 56.10% up from the average. CareTrust REIT, Inc. (NASDAQ:CTRE) has risen 46.70% since February 6, 2017 and is uptrending. It has outperformed by 30.00% the S&P500.

Investors sentiment decreased to 1.36 in 2017 Q3. Its down 0.10, from 1.46 in 2017Q2. It worsened, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 20 reduced holdings. 11 funds opened positions while 23 raised stakes. 46.97 million shares or 1.60% more from 46.23 million shares in 2017Q2 were reported. Moreover, Vanguard Group has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 5.44 million shares. Tiaa Cref Invest Limited Liability Company holds 0% or 271,415 shares in its portfolio. Deutsche Natl Bank Ag reported 0% stake. Rhumbline Advisers holds 120,231 shares or 0% of its portfolio. 13,841 are owned by Amalgamated Bankshares. Tower Research Capital Limited (Trc) holds 0% or 12,203 shares in its portfolio. Alyeska Invest Limited Partnership reported 635,853 shares. Principal Financial Group holds 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 16,914 shares. Sabby Management Ltd Liability Com holds 0.02% or 155,027 shares in its portfolio. California State Teachers Retirement Sys stated it has 0% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). State Board Of Administration Of Florida Retirement reported 19,240 shares. Point72 Asset Management Limited Partnership holds 0% or 400,000 shares in its portfolio. Schwab Charles Investment Mngmt reported 322,929 shares. Jpmorgan Chase And Comm reported 0% stake. 3.27M were reported by Fmr Ltd Liability Corp.

Since October 26, 2017, it had 1 insider purchase, and 2 insider sales for $7.00 million activity. Another trade for 8.00 million shares valued at $12.00M was bought by BAKER BROS. ADVISORS LP. Pillar Invest Corp also sold $4.52M worth of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $358.01 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

The stock increased 1.67% or $0.03 during the last trading session, reaching $1.83. About 2.49 million shares traded or 13.42% up from the average. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has risen 21.13% since February 6, 2017 and is uptrending. It has outperformed by 4.43% the S&P500.

Among 10 analysts covering Caretrust REIT (NASDAQ:CTRE), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Caretrust REIT had 23 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Thursday, August 3. The company was downgraded on Tuesday, January 3 by RBC Capital Markets. The stock of CareTrust REIT, Inc. (NASDAQ:CTRE) earned “Buy” rating by KeyBanc Capital Markets on Wednesday, August 23. The stock of CareTrust REIT, Inc. (NASDAQ:CTRE) has “Market Perform” rating given on Tuesday, July 26 by Wells Fargo. BMO Capital Markets initiated the stock with “Outperform” rating in Thursday, January 14 report. KeyBanc Capital Markets maintained CareTrust REIT, Inc. (NASDAQ:CTRE) rating on Friday, October 27. KeyBanc Capital Markets has “Buy” rating and $20.0 target. BMO Capital Markets maintained the stock with “Hold” rating in Thursday, November 9 report. BMO Capital Markets maintained the stock with “Hold” rating in Thursday, August 3 report. The firm has “Market Perform” rating given on Tuesday, June 20 by BMO Capital Markets. Canaccord Genuity maintained CareTrust REIT, Inc. (NASDAQ:CTRE) on Thursday, March 30 with “Buy” rating.

Leave a Reply

Your email address will not be published. Required fields are marked *